# A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects

> **NCT00664625** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 24 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** BMS-791325
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00664625
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2015-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00664625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00664625, "A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00664625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*